159 related articles for article (PubMed ID: 33794520)
1. Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly.
Kunisaki C; Sato S; Tsuchiya N; Kubo H; Watanabe J; Sato T; Takeda K; Tamura Y; Kasahara K; Kosaka T; Akiyama H; Endo I
Eur Surg Res; 2021; 62(1):40-52. PubMed ID: 33794520
[TBL] [Abstract][Full Text] [Related]
2. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
3. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
[TBL] [Abstract][Full Text] [Related]
4. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
5. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
6. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
7. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
Liang Y; Zhao L; Chen H; Lin T; Chen T; Zhao M; Hu Y; Yu J; Liu H; Li G
BMC Cancer; 2021 Feb; 21(1):196. PubMed ID: 33632161
[TBL] [Abstract][Full Text] [Related]
8. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.
Nishibeppu K; Komatsu S; Ichikawa D; Imamura T; Kosuga T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Otsuji E
BMC Cancer; 2018 Jan; 18(1):108. PubMed ID: 29382310
[TBL] [Abstract][Full Text] [Related]
9. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.
Hwang JE; Hong JY; Kim JE; Shim HJ; Bae WK; Hwang EC; Jeong O; Park YK; Lee KH; Lee JH; Cho SH; Chung IJ
Jpn J Clin Oncol; 2015 Jun; 45(6):541-6. PubMed ID: 25759484
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer.
Ogawa K; Honda M; Akashi Y; Inagawa S; Kaneda A; Hori S; Owada Y; Ohara Y; Hisakura K; Enomoto T; Shimomura O; Takahashi K; Oda T
Int J Clin Oncol; 2020 Oct; 25(10):1807-1813. PubMed ID: 32533352
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
[TBL] [Abstract][Full Text] [Related]
13. Appraisal of long-time outcomes after curative surgery in elderly patients with gastric cancer: a propensity score matching analysis.
Matsunaga T; Ishiguro R; Miyauchi W; Shishido Y; Miyatani K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Honjo S; Saito H; Fujiwara Y
BMC Surg; 2021 Jan; 21(1):33. PubMed ID: 33422067
[TBL] [Abstract][Full Text] [Related]
14. Different risk factors for three major recurrence patterns of pathological stage II or III gastric cancer patients who completed adjuvant S-1 monotherapy.
Kano Y; Ohashi M; Muneoka Y; Takahari D; Chin K; Yamaguchi K; Ida S; Kumagai K; Makuuchi R; Sano T; Nunobe S
Eur J Surg Oncol; 2021 Dec; 47(12):3097-3104. PubMed ID: 33931261
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
19. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
20. Impact of visceral adipose tissue on compliance of adjuvant chemotherapy and relapse-free survival after gastrectomy for gastric cancer: A propensity score matching analysis.
Matsui R; Inaki N; Tsuji T
Clin Nutr; 2021 May; 40(5):2745-2753. PubMed ID: 33933740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
